Home
>
US Stocks
>
Allakos Inc
Allakos Inc
ALLK

Allakos Inc (ALLK)

$108.2328.22%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
104.53
Today Low/High
103.5 / 108.25
52 Week Low/High
$75.41 / $157.98
Market Cap
$4.57B

Company Details

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.
Organisation
Allakos Inc
Headquaters
Redwood City, California, US
Employees
125
Industry
Health Technology
CEO
Robert Alexander

Discover more

Frequently Asked Questions

What is Allakos Inc (ALLK) share price today?

Can Indians buy Allakos Inc (ALLK) shares?

How can I buy Allakos Inc (ALLK) shares from India?

Can Fractional shares of Allakos Inc (ALLK) be purchased?

What are the documents required to start investing in Allakos Inc (ALLK) stocks?

We are a SEBI registered investement advisor